During the past decade, Fei Ma conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fei Ma" #1 collaborator was "CSPC Ouyi Pharmaceutical Co., Ltd." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Fei Ma" are "Breast Cancer" (2 trials), "Cardioncology" (1 trials) and "HER2 Gene Mutation" (1 trials). Many other conditions were trialed in "Fei Ma" in a lesser frequency.

Most popular intervention types in "Fei Ma" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Albumin-bound paclitaxel" (1 trials), "Pegylated Liposomal Doxorubicin" (1 trials), "Pyrotinib" (1 trials), "Record general information" (1 trials) and "Trastuzumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fei Ma" are 2 trials for "Female" genders and 1 trials for "All" genders.

Currently, there are NaN active trials in "Fei Ma". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Fei Ma, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Fei Ma, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".